Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

July 8, 2022

Study Completion Date

July 8, 2022

Conditions
Prostatic Cancer, Castration-Resistant
Interventions
DRUG

Darolutamide (Nubeqa, BAY1841788)

600mg, twice daily

DRUG

Enzalutamide

160mg, once daily

Trial Locations (7)

10461

Montefiore Medical Center, The Bronx

19004

MidLantic Urology - Bala Cynwyd, Bala-Cynwyd

27710

Duke University Medical Center, Durham

29579

Carolina Urological Research Center, Myrtle Beach

29607

Bon Secours St. Francis Hospital, Greenville

97239

Oregon Health and Science University, Portland

08043

New Jersey Urology, LLC, Voorhees Township

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY